The role of GRK2 in hypertension and regulation of GPR30 by Liu, Bonan
Western University 
Scholarship@Western 
Electronic Thesis and Dissertation Repository 
June 2012 
The role of GRK2 in hypertension and regulation of GPR30 
Bonan Liu 
Supervisor 
Dr. Robert Gros 
The University of Western Ontario 
Graduate Program in Pharmacology and Toxicology 
A thesis submitted in partial fulfillment of the requirements for the degree in Master of Science 
© Bonan Liu 2012 
Follow this and additional works at: https://ir.lib.uwo.ca/etd 
 Part of the Pharmacology Commons 
Recommended Citation 
Liu, Bonan, "The role of GRK2 in hypertension and regulation of GPR30" (2012). Electronic Thesis and 
Dissertation Repository. 578. 
https://ir.lib.uwo.ca/etd/578 
This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted 
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of 
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca. 
    
 
 
 
 
 
 
THE ROLE OF GRK2 IN HYPERTENSION AND  
REGULATION OF GPR30 
 
 
 (Thesis format: Monograph) 
 
 
by 
 
 
Bonan Liu 
 
 
Graduate Program in 
Pharmacology and Toxicology 
 
 
A thesis submitted in partial fulfillment  
of the requirements for the degree of  
Master of Science 
 
 
The School of Graduate and Postdoctoral Studies 
The University of Western Ontario 
London, Ontario, Canada 
 
 
© Bonan Liu, 2012  
    
ii 
 
THE UNIVERSITY OF WESTERN ONTARIO 
SCHOOL OF GRADUATE AND POSTDOCTORAL STUDIES 
 
 
CERTIFICATE OF EXAMINATION 
 
 
Supervisor 
 
______________________________  
Dr. Robert Gros 
 
Supervisory Committee 
 
______________________________  
Dr. Qingping Feng 
 
______________________________  
Dr. Peter Chidiac 
 
______________________________  
Dr. John Di Guglielmo 
 
 
Examiners 
 
______________________________  
Dr. Moshmi Bhattacharya 
 
______________________________  
Dr. Graham Wagner 
 
______________________________  
Dr. Dwayne Jackson 
 
 
 
 
 
The thesis by 
 
 
Bonan Liu 
 
entitled: 
 
The Role of GRK2 in Hypertension and Regulation of GPR30 
 
is accepted in partial fulfillment of the  
requirements for the degree of  
Master of Science  
 
 
Date__________________________ _______________________________ 
Chair of the Thesis Examination Board  
    
iii 
 
ABSTRACT 
In the hypertensive state, the expression of G protein-coupled receptor kinase 2 
(GRK2) level is elevated. On the other hand, the expression of GPR30, a recently 
discovered GPCR is greatly impaired. The current study focuses on investigating the 
roles of these two proteins in regulating G protein signaling under the normal and 
hypertensive states. Angiotensin II and vasopressin were used to examine the effects 
of GRK2 on Gq coupled GPCR signaling. ERK phosphorylation was proportionally 
enhanced with GRK2 over-expression. On the other hand, using arborization and 
wrinkle assays, I have shown that GRK2 acts as a negative regulator of Gs signaling in 
VSMCs. Aortic ring segments were used to examine the vascular reactivity mediated 
by GPR30. In WKY rats, the GPR30 agonists aldostrone and G1 attenuated 
phenylephrine mediated vasoconstriction, while the GPR30 antagonist G15 was able 
to block the effects of aldosterone but not G1. A wound assay was utilized to estimate 
the effects of GPR30 activation on endothelial cell migration and proliferation. The 
G1 effect on wound healing was also seen to be GPR30 independent and EC specific. 
Overall, these investigations suggest that altering GRK2 expression is able to regulate 
both Gq and Gs signaling in VSMCs. GPR30 plays a crucial role in vascular reactivity 
and growth regulatory mechanisms. However, GRK2 and GPR30 do not seem to 
co-localize or interact in the cell.  
 
Keywords:  GRK2, hypertension, GPR30, vascular, G protein signaling  
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1 INTRODUCTION 
1.1 Rationale of the study 
Hypertension or elevated arterial blood pressure affects 20% of the adult 
population in Western industrialized countries and is a major risk factor for 
myocardial infarction, renal failure and stroke (Lifton, 1996). Many neural, hormonal 
and cellular abnormalities have been described in the hypertensive state and therefore 
play an important role in the genesis as well as the maintenance of hypertension. 
However, the basic abnormality of hypertension appears to be increased peripheral 
resistance, which reflects a combination of both structural and functional changes to 
the vasculature (Folkow, 1982). Many different neural, endocrine, paracrine and 
autocrine factors interact with the vasculature to regulate tone and hence peripheral 
resistance. This regulation of vascular tone is in part mediated by the 
activation/inactivation of G protein-coupled receptors (GPCRs). In hypertension, 
alterations in GPCR activity/function have been described and appear to be related to 
alterations in GPCR kinase (GRK) activity/expression (Feldman & Gros, 1998, 
Feldman & Gros, 2006). Indeed, increased GRK2 expression has been observed in 
both human and animal models of hypertension (Gros et al, 1997, Gros et al, 2000). In 
addition, more recently the potential role of steroids (aldosterone and estrogen) 
regulating vascular function and cardiovascular disease have been of keen interest due 
to the discovery of a GPCR that can mediate the rapid effects of these steroids, namely 
GPR30. Indeed this GPR30 appears to mediate the rapid vascular effects of 
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aldosterone and estrogen (Gros et al, 2011a) and may therefore play an important role 
in the pathogenesis of hypertension, since both alterations in aldosterone and estrogen 
signaling have been implicated in cardiovascular disease (Feldman & Gros, 2011). 
Therefore, a better understanding of the acute regulation of vascular GRK2 and the 
potential interaction with the newly discovered GPCR steroid receptor (GPR30) with 
GRK2 are important. Thus, the focus of my thesis was: 1) to examine the effects of 
altering GRK2 expression levels in smooth muscle cells on GPCR signal transduction 
under normotensive and hypertensive conditions and 2) to examine whether GPR30 
function is regulated by GRK2.  
1.2 G-protein-coupled receptor kinases and hypertension 
1.2.1 Hypertension 
Hypertension is a risk factor for myocardial infarction, stroke, and ischemic heart 
disease. It has been among the top risk factors for death in North America, with an 
estimated 95% of the Canadian population predicted to be diagnosed with the disease 
at some point in their life. It often has a multifactorial onset relating to the interplay 
between environmental and genetic factors, including dietary habits, diabetes, and 
familial hypercholesterolemia (Harris et al, 2008). Due to its world-wide prevalence, it 
has become a subject of intensive research, especially because of the many 
mechanisms through which blood pressure is regulated. Neural and hormonal inputs 
play the largest roles in blood pressure regulation by maintaining a physiologic blood 
pressure of 120/80 mmHg in normotensive people (Feldman & Gros, 1998).  
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1.2.2 GPCR signaling in the vascular system 
In vascular smooth muscle cells (VSMCs), an important mechanism which 
mediates vasodilation is those GPCRs linked to adenylyl cyclase activation through 
the Gs-proteins (Maguire & Davenport, 2005). Although some of the beta-adrenergic 
mediated vasodilation is endothelial-dependent (Gros et al, 1994), the beta-adrenergic 
receptor represents the prototypical vasodilatory receptor in VSMCs. In endothelial 
cells, GPCRs linked to vasodilatory responses appear more complex and involve 
GPCRs linked to Gs (β-adrenergic receptors), Gi (muscarinic receptors) and Gq 
(endothelin-B receptors) resulting in the release of vasodilatory mediators such as 
nitric oxide, endothelium derived hyperpolarizing factors or prostacyclin (Maguire & 
Davenport, 2005). On the vasoconstrictor side, GPCRs such as endothelin, 
alpha-adrenergic and angiotensin receptors and others are linked to the activation of 
phospholipase C and/or inhibition of adenylyl cyclase via the activation of Gq-proteins 
and/or Gi-proteins in VSMCs (Feldman & Gros, 1998, Maguire & Davenport, 2005).  
1.2.3 Defects in GPCR-mediated vasodilation in hypertension 
Although enhanced activation of GPCRs linked to Gq and/or Gi-proteins 
mediating vasoconstriction have been reported in animal models of hypertension 
(Touyz & Schiffrin, 2000), many investigators have focused on the GPCR / Gs-protein 
/adenylyl cyclase complex to explain this defect in receptor-mediated vasodilation 
during the hypertensive state. The impairment in GPCR-mediated vasodilation 
appears to be at the level of the receptor. Since either direct acting vasodilators (e.g. 
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nitroprusside) or vasodilators acting distal to the receptor (e.g. forskolin or dibutyryl 
cyclic AMP) were not comparably impaired. The efficiency with which GPCRs 
interact with their G-proteins is in part dependent on the phosphorylation state of the 
receptor. GPCR phosphorylation is mediated by several different kinases, including 
the second-messenger dependent protein kinases such as protein kinase A and protein 
kinase C and by members of the G-protein receptor kinase family (GRKs) (Ferguson, 
2001).  
1.2.4 GRK and GPCR 
Signaling through a GPCR is under tight regulatory control. If a GPCR is 
subjected to prolonged or repeated stimulation, the receptor undergoes desensitization 
or down-regulation, which decreases its ability to activate appropriate G-proteins and 
initiate intracellular signaling cascades. This uncoupling is regulated in part by GRKs 
that phosphorylate agonist-bound GPCRs (Hargrave et al, 1993). GRK 
phosphorylation then increases the affinity of the GPCR for the arrestin class of 
proteins. These receptors can be recycled back to the membrane following 
dephosphorylation or targeted for down-regulation and degradation (Krupnick & 
Benovic, 1998). The binding of arrestin initiates down-regulation and prevents the 
GPCR from associating with its G-protein, thus reducing the functional activity of 
classical signaling paradigms for that receptor by up to 80% (Freedman & Lefkowitz, 
1996).  
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1.2.5 GPCR activation and desensitization 
As shown in Figure 1.1, activation of GPCRs following agonist binding induces a 
conformational change that promotes the exchange of GDP for GTP on the Gα subunit 
and allows the dissociation of the Gα and Gβγ subunits (Neer, 1995). Subsequently 
these G-protein subunits will interact and regulate the activity of a number of other 
effector molecules, such as adenylyl cyclase, phospholipase C, ion channels, tyrosine 
kinases and many others (Hamm, 1998). This conformational change also allows the 
GPCRs to bind one or more of the GRKs. The binding of GRKs, to the agonist 
occupied receptor, promotes the phosphorylation and desensitization of the GPCR, 
which promotes the binding of cytosolic proteins termed β-arrestins to the receptor. 
This leads to a further uncoupling of GPCRs from their G-proteins (Ferguson, 2001, 
Kohout & Lefkowitz, 2003).   
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Figure 1.1. Schematic of GPCR activation and desensitization. 1) Hormone (H) 
binding to GPCR leads to a conformational change of the GPCR, which leads to GDP 
release from α-subunit of the G-protein and facilitates the binding of GTP. This in turn 
allows the separation of the G-protein (into α and βγ) subunits which are then able to 
interact with various effector molecules (E). 2) Hormone (agonist)-occupied GPCRs 
also facilitates the binding of GRKs, which in turn phosphorylate and desensitize the 
GPCRs. 3) GRK-phosphorylated GPCRs are then further uncoupled from their 
G-proteins by the binding of β-arrestins (βarr). 4) Following β-arrestin binding 
GPCRs are subjected to internalization and de-phosphorylation in endosomes, and 5) 
recycled back to the membrane. Figure adapted from references (Feldman & Gros, 
1998, Ferguson & Caron, 1998, Metaye et al, 2005).   
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1.2.6 GRK family 
Although there are over 800 known GPCRs in the human genome and with over 
100 expressed within the cardiovascular system, it is surprising that only 7 GRKs have 
been identified (Penn et al, 2000). As shown in Figure 1.2, All GRKs have a similar 
basic structure with an N-terminal domain, a catalytic domain and a C-terminal 
domain. However, various post-translational modifications are responsible for their 
regulation within the cell. Based on functional and sequence similarities, the GRK 
family has been divided into three subfamilies: the rhodopsin kinase subfamily 
(GRK1 and GRK7), the beta-adrenergic receptor kinase subfamily (GRK2 and GRK3) 
and the others (GRK4, GRK5 and GRK6) (Premont et al, 1995). GRK1 and GRK7 are 
found almost exclusively in the retina and modulate opsins. GRK2 and GRK3 are 
widely expressed, although GRK2 is typically more abundant. GRK4 is found mostly 
in the testis and proximal tubule of the kidney. GRK5 and GRK6 are widely 
distributed among tissues. Therefore most GPCRs in the body are regulated by four 
GRKs: GRK2, GRK3, GRK5 and GRK6. Five of the seven GRKs (GRK1, 4, 5, 6 and 
7) are located at the membrane and near activated GPCRs, whereas GRK2 and GRK3 
are predominately located in the cytosol and undergo translocation and recruitment to 
the membrane following GPCR activation (Kohout & Lefkowitz, 2003, Penela et al, 
2003). GRK2 has been detected in VSMCs at the protein level (Ishizaka et al, 1997).   
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Figure 1.2. Schematic representation of GRK1-7 domain and regulatory sites. 
GRKs are multi-domain proteins which interact with, and are regulated by, many other 
cellular proteins. The figure depicts the conserved RGS (regulators of G-protein 
signaling) domain and the central catalytic domain, common to all seven GRKs. Also 
depicted are the different functional domains for phosphorylation and interactions 
with other cellular proteins. CaM, calcium calmodulin regulatory site; PH domain, 
pleckstrin homology binding domain; PL/PIP2 binding, phospholipids binding domain; 
 binding, G-protein  binding domain. GRK5 contains stimulatory (+) and 
inhibitory (-) auto-phosphorylation sites. Figure adapted from references (Ferguson, 
2001, Penela et al, 2003).   
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1.2.7 The role of GRK2 in vascular system 
GRK2 phosphorylates a range of GPCRs (Penn et al, 2000, Pitcher et al, 1998), 
some of which mediate vasodilation (via Gs-linked receptors) and some mediate 
vasoconstriction (via Gi and Gq-linked receptors). Therefore, in order for the increase 
in GRK2 expression/activity to have a role in the development and/or maintenance of 
hypertension, the increase of GRK2 in hypertensive state would be expected to 
predominately affect those receptors which mediate vasodilation without altering the 
activity of receptors mediating vasoconstriction. It is notable that such differential 
regulation of Gs-linked GPCRs but not Gq or Gi-linked receptors has been 
demonstrated in FRTL-5 cells over-expressing GRK2 (Iacovelli et al, 1999). However, 
inhibition of Gq-mediated signaling has been demonstrated in vascular smooth muscle 
cells over-expressing GRK2 (Peppel et al, 2000). Moreover, in transgenic mice with 
vascular smooth muscle-specific GRK2 over-expression, angiotensin II-mediated (Gq 
and/or Gi-linked) increases in blood pressure were almost completely attenuated 
(Eckhart et al, 2002). This transgenic model demonstrated elevated blood pressures. 
The net effect may depend on the expression level, the cellular regulation of GRK2, or 
the model of hypertension studied. In addition to the role of GRK2 in regulating the 
function of VSMCs, we propose to examine the role of GRKs in endothelial cells. 
GRK2 is expressed in endothelial cells and may act as the primary regulator of 
endothelial GPCR function (Tiruppathi et al, 2000, Vinge et al, 2001). In support of 
this hypothesis, a recent study demonstrated the crucial role of GRK2 in the regulation 
of sinusoidal endothelial cell nitric oxide synthase function in rats with portal 
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hypertension (Liu et al, 2005).  
1.2.8 GRK and hypertension 
GPCRs play a critical role in the regulation of vascular tone. As shown in Figure 
1.3, the coupling of GPCRs to different subclasses of G-proteins (Gs, Gi and Gq) 
allows for very diverse intracellular signaling events. Moreover, we and others have 
shown that GPCR-linked vasodilation is impaired during the hypertensive state. This 
impairment in GPCR-mediated vasodilation has been characterized as an uncoupling 
of the receptor from its G-protein (Feldman & Gros, 1998). G-protein-coupled 
receptor kinases (GRKs) phosphorylate and uncouple GPCRs from G-proteins and 
their effector systems. Several lines of evidence have now demonstrated increased 
GRK expression/activity in both human and animal models of hypertension (Eckhart 
et al, 2002, Felder et al, 2002, Gros et al, 1997, Gros et al, 1999, Gros et al, 2000, 
Ishizaka et al, 1997, Keys et al, 2005). Taken together, all these studies demonstrate a 
potential crucial role for GRKs in the pathogenesis and/or maintenance of 
hypertension. However, GRKs can mediate the phosphorylation of many different 
GPCRs, including those GPCRs linked to both vasodilation and vasoconstriction 
(Pitcher et al, 1998). Why increased GRK expression preferentially affects those 
GPCRs linked to vasodilation during the hypertensive state is still unclear.   
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Figure 1.3. GPCR signaling in vascular smooth muscle cells. Activation of Gs 
stimulates adenylate cyclase (adenylyl cyclase), which leads to the formation of 
cAMP and subsequent phosphorylation of intracellular targets by PKA (protein kinase 
A). PKA phosphorylation causes increased relaxation in smooth muscle cells 
ultimately leading to vasodilation. Gi/o, on the other hand, inhibits adenylate cyclase 
activity, decreasing cAMP formation and PKA phosphorylation, effectively 
decreasing relaxation and diminishing vasodilation. Gq activates PLC (phospholipase 
C) leading to the formation of IP3 (inositol 1,4,5-trisphosphate) and DAG 
(diacylglycerol). IP3 initiates Ca2+ release from intracellular stores, which activates 
Ca2+-CaM (calmodulin), leading to contraction. Additionally, DAG activates PKC 
(protein kinase C), which also phosphorylates target proteins that facilitate smooth 
muscle contraction leading to vasoconstriction.   
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1.3 G-protein-coupled Receptor 30 and cardiovascular function 
Steroid hormones such as aldosterone and estradiol have been increasingly 
appreciated as important physiological and pathophysiological regulators of 
cardiovascular functions. These hormones were conventionally thought to act solely as 
transcriptional regulators. However, it is now known that they mediate their actions 
both via “classical” transcriptional mechanisms as well as via “rapid” (previously 
termed “nongenomic”) mechanisms. A recently recognized G protein coupled receptor, 
GPR30 has been shown to mediate some of the rapid effects of estradiol and 
aldosterone (Figure 1.4).  
1.3.1 Cellular location and signaling of GPR30 
Although ERα and ERβ are accepted as the predominant nuclear receptors 
involved in the genomic effects of estrogen, evidence also indicates that rapid 
modulation of cell-signaling pathways occurs via a subpopulation of ERs located at 
the plasma membrane (Edwards, 2005), which has fueled the speculation about a role 
of GPR30 (Levin, 2011). The localization of GPR30, however, seems to be 
predominantly intracellular (Otto et al, 2008), consistent with reports that describe the 
constitutive internalization of plasma membrane GPR30 (Sanden et al, 2011).  
Signaling through GPR30 occurs via transactivation of the epidermal growth 
factor receptor (EGFR) and involves nonreceptor tyrosine kinases of the Src family 
(Filardo et al, 2000). In this mechanism, which is now also accepted for other 
G-protein-coupled receptors (Bhola & Grandis, 2008), stimulation of GPR30 activates 
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metalloproteinases and induces the release of heparin-binding EGF, which binds and 
activates EGFR (Prenzel et al, 1999), leading to activation of downstream signaling 
molecules, such as ERK1/2 (Edwin et al, 2006). Moreover, 17β-estradiol-mediated 
activation of GPR30 stimulates production of cAMP, intracellular calcium 
mobilization and PI3K activation (Revankar et al, 2005, Thomas et al, 2005). Further 
research in human breast cancer cells suggests that sphingosine kinase (Sukocheva et 
al, 2006) and integrin α5β1 (Quinn et al, 2009) are intermediates in 
17β-estradiol-mediated EGFR transactivation; the latter study suggesting a role for 
GPR30 in fibronectin assembly.  
In addition to the above-mentioned rapid signaling events, GPR30 also regulates 
transcriptional activity, albeit indirectly, by activating signaling mechanisms that 
involve cAMP, ERK and PI3K (Meyer et al, 2009). The genes regulated by GPR30 
include FOS, which encodes c-Fos (Maggiolini et al, 2004), a protein that forms a 
heterodimer with various other proteins to form the transcription factor AP-1. In turn, 
these signaling pathways also activate other transcription factors, such as 
steroidogenic factor 1 (Lin et al, 2009), which induce expression of additional genes 
(Prossnitz & Maggiolini, 2009).   
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Figure 1.4. Structures of aldosterone (Aldo), 17β-estradiol (E2), GPR30-selective 
agonist (G1) and antagonist (G15). G1 and G15 have similar structures as that of 
aldosterone or estradiol. They can bind to the extracellular domains of GPR30.   
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1.3.2 Steroid hormones mediated rapid vascular and metabolic effects 
Clinical trials have suggested that aldosterone and estradiol have effects beyond 
those mediated via their “classical pathways”. For example, in patients with 
congestive heart failure or following myocardial infarction, the beneficial effects of 
aldosterone antagonists have been demonstrated (Pitt et al, 1999, Pitt et al, 2003) - not 
explainable by their weak diuretic effects. These observations have triggered the 
ongoing study of mechanisms by which aldosterone might mediate the detrimental 
cardiovascular effects that are alleviated by aldosterone antagonists. Our studies have 
demonstrated rapid aldosterone actions on vascular reactivity (Liu et al, 2003), single 
cell contractility (Gros et al, 2007) and growth regulatory mechanisms due to 
activation of several receptors, including GPR30 (Figure 1.5). In regards to estradiol, 
its potentially beneficial cardiovascular effects have long been appreciated (Miller & 
Duckles, 2008).  
However, the mechanisms underlying the “paradoxical” detrimental 
cardiovascular effects of postmenopausal estrogen treatment seen in randomized 
clinical trials (Grady et al, 2002, Rossouw et al, 2002) have suggested that estradiol 
might mediate both beneficial and detrimental effects. Our recent studies have 
demonstrated that estradiol could have diametrically opposite effects on vascular 
smooth muscle function, depending on whether GPR30 or the estrogen receptor (ER) 
was activated (Ding et al, 2009). In summary, estradiol and aldosterone activation of 
both “classical” steroid receptors (MR, ER) and GPR30 are important in 
cardiovascular and metabolic regulation. Delineating which steroids interact with 
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which receptors in the regulation of which processes would be the first step in 
developing novel therapeutic approaches to selectively modulate their pathobiological 
actions.  
1.3.3 The role of GPR30 in steroid hormone-mediated vascular effects 
Recent studies have indicated that the rapid vascular effects of aldosterone and 
estrogen are mediated by both their classical receptors (MR and ER, respectively) as 
well as by GPR30 (Gros et al, 2011a). GPR30 was initially characterized as mediating 
the rapid effects of estrogen (Revankar et al, 2005). GPR30 is a widely expressed 
GPCR (expressed in heart, arteries, breast, lung, central nervous system and 
leukocytes) (Hasbi et al, 2005) and is detectable in freshly isolated vascular smooth 
muscle cells (Ding et al, 2009) as well as in vascular endothelial cells (Gros et al, 
2011b). GPR30 has been studied predominantly in the context of reproductive biology 
and cancer biology. Initial studies primarily focused on GPR30’s growth regulating 
effects (Ahola et al, 2002, Albanito et al, 2007, Filardo, 2002, Vivacqua et al, 2006b), 
the impact of its expression on cancer survival (Filardo et al, 2006, Smith et al, 2007, 
Vivacqua et al, 2006a) and GPR30’s actions on oocyte maturation (Kolkova et al, 
2010, Pang & Thomas, 2010, Wang et al, 2007).   
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Figure 1.5. Schematic depiction of divergent pathway activation by estrogen and 
aldosterone acting through ERα/MR and/or GPR30-linked pathways resulting in 
the activation or inhibition of ERK activity/ERK-dependent apoptosis. PI3K: 
Phosphoinositide-3 kinase; PKA: Protein kinase A. Figure adapted from reference 
(Feldman & Gros, 2011)  
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1.3.4 GPR30 and regulation of vascular reactivity 
Studies of the cardiovascular effects of GPR30 have mostly focused on its effects 
on vascular reactivity. GPR30 activation lowers blood pressure both acutely (Haas et 
al, 2009) and chronically (Lindsey et al, 2009). Genetic deletion of GPR30 has been 
associated with sex-specific increases in blood pressure (Martensson et al, 2009), 
although we are aware that the generalizability of this finding in other GPR30 deletion 
models has not been universal (Langer et al, 2010). Our studies demonstrated that, in 
vascular smooth muscle cells, GPR30 activation mediates myosin light chain 
phosphorylation (Gros et al, 2007, Gros et al, 2011b). However, since the overall 
effect of vascular GPR30 activation is vasodilatory and GPR30-mediated vasodilation 
is endothelium-dependent (Broughton et al, 2010), this would suggest that 
understanding how GPR30 regulates endothelial cell-based mechanisms is critical for 
understanding how GPR30 regulates vascular reactivity.  
1.3.5 The effect of GPR30 on the regulation of vascular growth 
As noted above, GPR30 activation has prominent effects in regulating cancer cell 
growth. GPR30’s role in regulating cardiovascular cell growth is unknown, but could 
be important in settings where vascular cell growth is stimulated- e.g., following 
vascular injury or occlusion. Recent studies by our laboratory have shown that in 
vascular smooth muscle cells GPR30 activation is pro-apoptotic and is directly 
antagonist to the anti-apoptotic consequences of ERα activation. In other cell systems 
GPR30 activation has been linked to either anti-proliferative/pro-apoptotic (Ariazi et 
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al, 2010, Chan et al, 2010) or pro-proliferative/anti-apoptotic (He et al, 2009, Lin et al, 
2009, Pandey et al, 2009) consequences. The role of GPR30 in regulating endothelial 
cell growth is unknown. Our in vitro observations (Ding et al, 2009) showed that 
GPR30 expression is down-regulated in the setting where vascular smooth muscle 
cells undergo the phenotypic switch from a contractile to a synthetic cell type 
following primary culture (Li et al, 1999). A similar switch to a synthetic phenotype 
occurs with vascular injury (Clowes et al, 1983). Based on our preliminary studies 
suggesting that GPR30 is down-regulated in vascular smooth muscle cells following 
injury, we propose that reversal of this down-regulation of GPR30 response might 
have a significant effect on the smooth muscle response to injury. Together, these 
studies delineated the effect of GPR30 on the regulation of vascular growth.  
1.4 Research objectives 
Based on the data presented in the introduction of this thesis, I hypothesized the 
following:  
1) The extent of GRK2 content is essential for the development and maintenance of 
the vascular hypertensive phenotype.  
2) GPR30 plays a crucial role in vascular reactivity and growth regulatory 
mechanisms.  
3) GRK2 mediates the desensitization of GPR30 and regulates GPR30 signaling.   
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2 MATERIALS AND METHODS 
2.1 Animal protocols 
Male Wistar-Kyoto rats (WKY) and spontaneously hypertensive rats (SHR) 
(10-12 weeks of age; Charles River, Pointe-Claire, QC) were utilized in our studies. 
They were cared for in accordance with the Canadian Council on Animal Care 
guidelines and housed under a 12 hours light/dark cycle with free access to standard 
laboratory chow and drinking water. The protocol for their use was approved by the 
Animal Use Subcommittee (AUS) of the University of Western Ontario. Systolic 
blood pressure was determined via tail-cuff plethysmography as previously described 
(Gros et al, 2000). Mean systolic pressures in SHR were significantly higher 
compared with WKY rats.  
2.2 Rat aortic vascular smooth muscle cell primary cultures 
Rat aortic vascular smooth muscle cell (VSMC) primary cultures were isolated by 
a modification of the methods of Touyz et al. (Touyz et al, 1994). Briefly, freshly 
isolated aortas from both normotensive and hypertensive rats were concurrently 
digested using collagenase and elastase incubations as we have previously described 
(Gros et al, 2006b). Rats were anaesthetized, and the chests were opened. The aortas 
were located, dissected out, and placed in ice-cold PBS. Blood and connective tissue 
were removed, and the aortas were cut into longitudinal strips. Aortic tissue strips 
from 2 aortas were placed in a sterile 50 ml centrifuge tube (Falcon, VWR Canlab, 
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Mississauga, ON) containing 1 mg/ml collagenase (Worthington Biochemical 
Corporation, Lakewood, N.J.) in 5 ml of Ham’s F12 medium (Gibco BRL, Burlington, 
ON) supplemented with 1% gentamicin and 10% FBS, and incubated at 37°C for 20 
minutes. The medium was aspirated and replaced with 5 ml of fresh medium 
containing 1 mg/ml collagenase, and incubated at 37°C for 30 minutes. An additional 
5 ml of medium containing 1 mg/ml collagenase was added to the tube and incubated 
for another 30 minutes. The tube was then centrifuged for 5 minutes at 2000 rpm at 
room temperature and the supernatant was aspirated. The tissue pellet was 
resuspended in 5 ml of medium containing 1 mg/ml collagenase and 0.5 mg/ml 
elastase (Worthington Biochemical Corporation, Lakewood, N.J.), and incubated at 
37°C, shaking periodically, for 90 minutes. The solution was collected with a pipette 
and filtered through a sterile 100 μm cell strainer (Nitex, VWR Canlab, Mississauga, 
ON) into another sterile 50 ml conical tube. The filter was washed with 5 ml 
Dulbecco's modified Eagle's medium (DMEM) (Gibco BRL, Burlington, ON). The 
filtered solution was centrifuged for 5 minutes at 2000 rpm at room temperature and 
the supernatant was aspirated. Finally, the pellet was resuspended in DMEM 
supplemented with 10% FBS, 1% fungizone and 0.1% gentamicin, and the cells were 
plated onto 100 mm culture dishes. Cells were maintained in a Hera Cell incubator 
(TC Tech Products, Maple Plain, MN) at 37°C and 5% CO2. VSMCs were used 
between passages 4 and 12 for all experiments. Both early and late passages of cells 
were used for all assays to negate the possibility of differential effects reflected 
because of passage-specific differences in VSMCs.  
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2.3 Rat aortic endothelial cell cultures 
Rat aortic endothelial cells (ECs) were purchased from Cell applications Inc. (San 
Diego, CA) and cultured according to the instructions of the supplier as we have 
recently described (Gros et al, 2011b). Growth medium, subculture reagent kit and 
attachment factor solutions were also purchased from Cell applications Inc. Culture 
dishes were precoated with Attachment Factor Solution for 30 minutes at 37°C or 2 
hours at room temperature. When subculturing ECs, monolayer of cells were washed 
with HBSS, and 5 ml of Trypsin/EDTA Solution was pipetted into the culture dish. 
After gently rocking the dish, 3 ml of the solution was removed immediately. When 
most of the cells were detached, 5 ml of Trypsin Neutralizing Solution was added to 
the dish to inhibit further tryptic activity. The cell suspension was then transferred to a 
14 ml sterile conical tube and centrifuged at 1000 rpm for 5 minutes. The supernatant 
was aspirated from the tube without disturbing the cell pellet. Finally, cells were 
resuspended in 10 ml of Rat Endothelial Cell Growth Medium and inoculated into 
Attachment Factor Solution coated dishes. ECs were utilized between passages 4 and 
10.  
2.4 GRK2 protein expression in vascular smooth muscle cells 
Assessment of GRK2 protein expression was determined by immunoblotting as 
previously described (Gros et al, 2000). Briefly, cultured VSMCs from WKY and 
SHR rats were washed with PBS and were lysed with ice-cold lysis buffer (40 mM 
Tris-HCl, pH 7.4, 274 mM NaCl, 2% Nonidet P-40 and 1 EDTA-free protease 
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inhibitor cocktail tablet (Roche Diagnostics, Indianapolis, IN)). Cells were scraped off 
the dishes, placed into labeled eppendorf tubes, and centrifuged at 13 000 rpm for 10 
minutes at 4°C. The protein concentration of the supernatant within the samples was 
then measured using a bicinchoninic acid (BCA) assay (Thermo Scientific, Rockford, 
IL). In this assay, 10 μl of the sample supernatant was added to 3 ml of the BCA 
reagents and the solutions were incubated for 30 minutes at 37°C. The absorbance of 
the samples was then read at 562 nm using a Spectronic 20 spectrophotometer 
(Bausch & Lomb, NY). Equal protein concentrations of the samples were then run on 
a 10% SDS-PAGE gel in addition to a Precision Plus Protein Dual Color Standards 
Marker (Bio-Rad, Hercules, CA). The gels were blotted electrophoretically onto an 
Immuno-Blot polyvinylidene fluoride membrane (Bio-Rad, Hercules, CA). The 
membranes were then blocked with 5% blocking buffer (Tris-Buffered saline, 
tween-20 (TBS-T), powdered Skim Milk) and incubated at 4°C overnight in 1:1000 
GRK2 antibody (Santa Cruz Biotechnology, Santa Cruz, CA), followed by a 30 
minutes wash with TBS-T, then 1:5000 anti-rabbit antibody (Sigma-Aldrich, Oakville, 
ON) for 1 hour at room temperature. The blots were then washed again for 30 minutes 
with TBS-T. GRK2 protein bands were then detected and visualized by enhanced 
chemiluminescence according to the protocol described by the assay manufacturer 
(PerkinElmer Life and Analytical Sciences, Waltham, MA). Western blots were then 
analyzed using Scion Imaging for Windows software (Frederick, MD), which 
determined the intensity of the bands of proteins of interest.  
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2.5 Adenoviral constructs 
Adenoviral constructs were generated with AdMax
TM
 adenovirus vector creation 
kit as per manufacturer’s instructions (Microbix BioSystems Inc., Toronto, ON) as we 
previously described (Gros et al, 2011b). Briefly, GFP, GRK2 or GPR30 cDNA were 
generated by PCR using plasmid templates of GFP cDNA (Clontech, Mountain View, 
CA), GRK2 or GPR30 (ATCC), the resultant cDNAs were subcloned into shuttle 
vector pDC316 and purified. For adeno siRNA constructs, the small interfering RNA 
(siRNA) sequences specific for GFP (bp 418-438), GRK2 (bp 710-730) and GPR30 
(bp 356-376) were cloned into the modified pDC312 vector. The recombinant plasmid 
was then co-transfected into human embryonic kidney (HEK) 293 cells with 
adenoviral DNA pBHGlox (delta) E1, 3Cre. Recombinant adenovirus was harvested 
by lysis of transfected HEK293 cells using 3 freeze/thaw cycles. For gene transfer, 
VSMCs or ECs were infected with adenoviral constructs for 24 hours at 37 °C, 
following which, medium was disposed of and replenished. Cells were utilized for 
experimentation 48 hours after gene transfer.  
2.6 GRK2 over-expression & knockdown by adenoviral infection 
WKY and SHR VSMCs were infected with increasing concentrations of GRK2 or 
SiGRK2 adenovirus, GFP or SiGFP virus was used as control. The media was 
changed once after 24 hours. 48 hours post-infection, VSMCs were washed with PBS 
and lysed with ice-cold lysis buffer (40 mM Tris-HCl, pH 7.4, 274 mM NaCl, 2% 
Nonidet P-40 and 1 EDTA-free protease inhibitor cocktail tablet (Roche Diagnostics, 
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Indianapolis, IN)). Western blots were used to determine the virus concentration 
needed to increase or decrease GRK2 protein expression levels by approximately 
50%.  
2.7 Immunoblotting for ERK phosohorylation 
To examine the rapid effects of “vasoconstrictor” hormones acting through 
GPCRs linked to Gq signaling, I examined the short-term effects of angiotensin II and 
vasopressin. The effects of these hormones on ERK activation were compared with 
that of platelet-derived growth factor (PDGF, hormone acting through a tyrosine 
kinase receptor pathway, as opposed to a GPCR pathway). As previously described 
(Gros et al, 2006a), VSMCs were infected with GRK2 or SiGRK2 adenovirus for 24 
hours. After serum starvation for 24 hours, cells were incubated in the presence or 
absence of 1 μM angiotensin II, 1 μM vasopressin, or 20 ng/ml PDGF at 37°C for 5 
minutes. VSMCs were then washed twice with ice-cold PBS and directly lysed in a 
buffer containing 10 mM Tris-HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl2, 0.3% 
Nonidet P-40, and 1 mM Na3VO4 with 1 mM phenylmethylsulfonyl fluoride. The cell 
lysates were centrifuged at 13000 rpm for 10 minutes at 4°C. 50 μg of protein was 
resolved on 10% SDS-PAGE and blotted electrophoretically onto Immun-Blot 
polyvinylidene fluoride membrane (Bio-Rad, Hercules, CA). The membranes were 
blocked with 5% skim milk and incubated with either 1:1000 anti-phospho-ERK1/2 or 
1:1000 anti-ERK1/2 (BD Transduction Laboratories, Lexington, KY), followed by 
1:5000 anti-rabbit antibody (Sigma-Aldrich, Oakville, ON). Bands were visualized by 
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chemiluminescence as described by the manufacturer's protocol (PerkinElmer Life 
and Analytical Sciences, Boston, MA). Total-ERK1/2 was used as loading control.  
2.8 Arborization of VSMCs in response to drug treatment 
Short-term β-adrenergic effects on contractile function were determined by 
assessment of the extent of vascular smooth muscle arborization (Nabika et al, 1985, 
Nabika et al, 1988). The arborization response mediated by elevation of cAMP has 
been linked to cytoskeletal changes, including reorganization of actin fibers 
(Ben-Ze'ev & Amsterdam, 1987, Westermark & Portor, 1982) and assembly of 
microtubules (Nabika et al, 1985). As previously described (Gros et al, 2006a), 
VSMCs were cultured onto 35 mm dishes. Cells were infected with GFP, SiGFP, 
GRK2, or SiGRK2 adenovirus for 24 hours before being serum-starved for another 24 
hours using starvation medium (DMEM supplemented with 0.1% FBS, 50 units/ml 
gentamicin, and 1% Fungizone). Following serum starvation, the medium was then 
replaced by M199 medium and the cells were returned to the incubator for 15 minutes 
and then transferred to a temperature controlled chamber for another 15 minutes 
maintained at 37°C (Bionomic controller; 20/20 Technology Inc., Wilmington, NC) 
on an inverted microscope (Axiovert S100; Carl Zeiss, Thornwood, NY). Cells were 
then treated with either isoproterenol (ISO, 10 μM) or forskolin (FSK, 10 μM) 
obtained by Sigma-Aldrich (Oakville, ON). The progression of the arborization 
response was measured in the dark using time-lapse video microscopy. One picture 
was taken prior to treatment to show the initial morphology of the cells and this 
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baseline served as a control. The other picture was obtained after 40 minutes and the 
extent of arborization was assessed by determining the change in image intensity 
using the threshold setting within the image analysis software (Northern Eclipse 6.0; 
Empix Imaging, Toronto, ON) (Figure 2.1). The change in image intensity was 
expressed as a percentage of basal intensity (before the addition of drug).   
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C.                             D. 
   
 
 
 
 
 
Figure 2.1. Representative images of VSMCs arborization. I utilized the 
arborization “retraction” process of cultured VSMCs as a measure of functional 
responses to Gs-mediated GPCR activation. Arborization is a rapid and striking 
morphological change of vascular smooth muscle cells, characterized by central cell 
rounding and the presence of long branching processes. It is caused by increased 
cAMP and has been proposed as an index of vasodilator reactivity. A. baseline; B. 40 
minutes post-10 μM ISO treatment; C. baseline upon thresholding; D. threshold of 40 
minutes post-10 μM ISO treatment.    
100 micron 100 micron 
100 micron 100 micron 
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2.9 Assessment of VSMCs contractility using the silicone wrinkle assay 
This assay was modified from the methods of Harris et al. (Harris et al, 1980). As 
recently described (Gros et al, 2011a), small drops of silicone were placed in the 
center of glass cover slips and were allowed to flatten by gravity. The glass cover slips 
were then passed through a Bunsen burner flame to cross-link the top layer of the 
silicone, to permit subsequent cell attachment, and placed in culture dishes (35 mm 
diameter). VSMCs were seeded on the siliconized cover slips at a density of 2.5 × 10
5
 
cells/ml, and maintained in DMEM supplemented with 10% FBS, gentamicin, and 
fungizone. The VSMCs attach to the polymerized silicone, resulting in substrate 
deformation of the weakly cross-linked top silicone layer. The DMEM was replaced 
with Medium 199 (Gibco) with Hank’s salts, L-glutamine, and 25 mmol/L HEPES 
buffer, without FBS, 18 hours before contractility measurements, and cells were 
maintained in an incubator until assay. To assess substrate deformation, an indirect 
measure of VSMCs tone, 35 mm dishes containing the siliconized cover slips were 
mounted in a temperature-controlled chamber (37 °C, Bionomic controller BC-100, 
20/20 Technology, Inc., Wilmington, NC) on an inverted microscope (Zeiss, Axiovert 
S100). Cells were allowed to stabilize in this microscope chamber for 15 minutes prior 
to treatment. After 10 minutes of baseline recording, increasing doses of ISO or FSK 
(0.1 nM-10 µM) were given to VSMCs at 5 minutes intervals. Contractile responses 
were assessed using time-lapse video microscopy. Wrinkle area was quantified using 
bright image thresholding (Northern Eclipse 6.0, Empix Imaging, Toronto, ON), 
where the relaxation was reflected as decreased intensity (Figure 2.2). Contractile 
responses were expressed relative to baseline intensity measured before treatment.   
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Figure 2.2. Representative microscopic samples (magnification 400X) illustrating 
wrinkles and thresholding of VSMCs using the silicone wrinkle assay. The 
intensity of the wrinkles significantly decreased (indicated by arrows); the highlighted 
areas were analyzed and quantitated by area and pixel intensity. A. baseline wrinkles; 
B. relaxation and loss of wrinkles due to ISO treatment; C. baseline wrinkles upon 
thresholding; D. threshold of relaxation and wrinkle loss due to ISO treatment.   
25 micron 
25 micron 25 micron 
25 micron 
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2.10 GPR30 protein expression in heart, aorta and VSMCs 
Freshly isolated hearts and aortas from normotensive WKY and hypertensive 
SHR rats were washed with ice-cold PBS, transferred into lysis buffer, chopped into 
small pieces with dissecting scissors, homogenized using a disposable pestle system 
(Fisherbrand) and then centrifuged at 13000 rpm for 10 minutes, at 4˚C. The resultant 
supernatants were collected for western blotting. VSMCs were isolated from aorta of 
WKY rats as described in section 2.2. Cells (passages 0-2) were washed with PBS and 
lysed with ice-cold lysis buffer. Proteins were separated by SDS-PAGE, transferred to 
PVDF membrane and immunoblotted for GPR30 content as we recently described 
(Gros et al, 2011a). GPR30 antibody (1:500) was obtained from MBL International 
(Woburn, MA).  
2.11 Assessment of vascular reactivity in aortic rings 
To investigate the potential vasodilatory role of GPR30, I examined its vascular 
reactivity in aortic rings according to previously published methods (Gros et al, 1994, 
Liu et al, 2003), WKY rats were anesthetized, the chest wall was opened, and a 
portion of aorta was removed quickly to a Petri dish containing ice-cold Krebs 
physiological salt solution (KPSS) of the following composition (mM): NaCl 118.0, 
NaHCO3, 25.0, d-glucose 11.1, KC1 4.72, CaCl2 2.56, NaH2PO4 1.13, and MgCl2 1.12. 
(-)Ascorbic acid (0.114 mM) and disodium EDTA (0.0297 mM) were added to 
stabilize test drugs.  
Blood and connective tissue were removed carefully, and four ring segments (3 
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mm wide) from each aorta were cut and suspended in KPSS under optimal tension 
(0.75 g) in double-walled organ baths maintained at 37°C and gassed with 5% CO2 
and 95% O2 individually. The rings were equilibrated for 60 minutes, during which 
time they were maximally constricted with phenylephrine (PE, final bath 
concentration, 10 μM) twice, KPSS was changed three times after each dose and the 
tension was adjusted as necessary. In experiments with endothelium-denuded aortic 
rings, the endothelial layer was removed by gentle rubbing and flushing with distilled 
water. The absence of functional endothelium was inferred by the loss of 
methylcholine-mediated relaxation in PE-preconstricted rings. Tension generated was 
measured using isometric Force Displacement Transducers (Model FT03) and 
Compact Transducer Amplifiers (Model P11T, Grass Technologies, West Warwick, 
RI), which linked through a Data Acquisition System (DI-720 Series) to the computer. 
WinDaq Data Acquisition Software (DATAQ Instruments, Inc., Akron, OH) was used 
to record the waveform and analyze data.  
Following the equilibration period, rings were submaximally constricted with PE 
(final bath concentration, 100 nM) and allowed to reach a plateau that remained stable 
for 15 minutes (baseline). After washout of PE, aortic rings were incubated in the 
presence or absence of 1 μM G15, and increasing concentrations of aldosterone (Aldo, 
10 pM-100 nM) or G1 (1 nM-1 μM). G15 was added 15 minutes before the addition 
of PE. Aldo or G1 was added 2 minutes before PE. In each experiment, one or two 
rings were assessed after sequential cycles of PE-mediated constriction without other 
treatment and thus served as temporal controls. PE-mediated constriction was 
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quantified by determining the area under the curve (AUC) using a trapezoidal method 
of analysis (Figure 2.3). The effects of G15, Aldo or G1 on PE-mediated contraction 
responses were expressed as a percentage of baseline response normalized for 
temporal changes as assessed in the parallel control ring segments.   
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Figure 2.3. Representative tracings from control and aldosterone-treated aortic 
ring segments. Aldo attenuated PE-mediated constriction in endothelium-intact aortic 
ring segments. Constriction response with PE was quantified by determination of 
AUC using trapezoidal method of analysis.   
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2.12 Wound healing assay 
To determine the effect of GPR30 on cell migration and proliferation, I performed 
a wound healing assay. The wound healing assay has been carried out for many years 
to estimate the migration and proliferation rates of different cell types and under 
differant culture conditions (Denker & Barber, 2002). ECs or VSMCs were infected 
with GFP, SiGFP, GPR30 or SiGPR30 adenovirus as described in section 2.5. 
Forty-eight hours post-infection, cells were nearly confluent (~90%) in 35 mm dishes. 
A sterile 10 μl pipet tip was used to scratch wounds through the cells perpendicular to 
a line drawn on the bottom of the dish (Figure 2.4). After changing the medium, cells 
were pretreated in the presence or absence of the GPR30 antagonist G15, and then 
treated with vehicle or GPR30 agonist aldosterone, estradiol or G1. Wound area was 
then inspected microscopically and pictures were taken every 8 or 24 hours. The open 
gaps (wounds) were calculated as percentage of basal area using image analysis 
software (Northern Eclipse 6.0; Empix Imaging, Toronto, ON).   
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Figure 2.4. Wound healing assay was used to estimate the migration and 
proliferation rates of cultured cells. Aortic ECs or SMCs from WKY rats were 
nearly confluent (~90%) in 35 mm dishes. A sterile 10 μl pipet tip was used to scratch 
wounds through the cells perpendicular to a line drawn on the bottom of the dish. 
Cells were infected with adenovirus or treated with different drugs (e.g. G1). Wound 
area was then inspected microscopically and pictures were taken at the indicated time 
points. The open gaps (wounds) were calculated as percentage of basal area using 
image analysis software (Northern Eclipse 6.0; Empix Imaging, Toronto, ON).   
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2.13 Immunofluorescence assay 
To investigate whether GPR30 can co-localize with GRK2, I performed double 
immunofluorescence experiment. VSMCs isolated from WKY and SHR rats were 
cultured in 60 mm dishes. Some dishes were infected with FLAG-tagged GPR30 
adenovirus for 4 hours. Twenty-four hours post-infection, cells were seeded onto 35 
mm glass bottom microwell dishes at 30-50% confluency. After incubation in the 
presence or absence of 10 pM Aldo or 1 μM G1 for 15 minutes, cells were fixed using 
2% paraformaldehyde for 15 minutes, permeabilized in 100% methanol for 10 minutes, 
and subsequently blocked with 3% BSA for 1 hour to reduce nonspecific staining. Cells 
were then incubated with mouse-anti-FLAG (1:500, Sigma-Aldrich, Oakville, ON) and 
rabbit-anti-GRK2 antibodies (1:500, Santa Cruz Biotechnology, Santa Cruz, CA) at 
4°C overnight. Following washes with PBS, cells were probed with AlexaFluor 488 
goat-anti rabbit and AlexaFluor 594 goat-anti mouse secondary antibodies (1:1000, 
Invitrogen) for 1 hour at room temperature in the dark. DAPI was used to detect nuclei. 
As a negative control, the primary antibody was omitted from the staining procedure. 
Finally, cells were visualized through a Zeiss LSM 410 confocal microscope equipped 
with a Krypton / Argon laser using a 63× oil immersion lens.  
2.14 Co-immunoprecipitation of GPR30 and GRK2 
To determine whether GPR30 interacts with GRK2, I performed co-IP experiment. 
VSMCs isolated from WKY rats were infected with adenovirus encoding GFP or 
FLAG-tagged GPR30. The media was changed once after 24 hours. Forty-eight hours 
post-infection, cells were treated in the presence or absence of 10 pM Aldo or 1 μM 
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G1 for 15 minutes and then harvested. After washing with PBS and spinning, the cell 
pellet was resuspended in lysis buffer. The samples were centrifuged at 13000 rpm for 
10 minutes and the supernatants were transferred to new microcentrifuge tubes. 500 μl 
of supernatant was incubated with 50 μl of a 50% slurry of lgG agarose beads 
(equilibrated in lysis) for 1 hour and subjected to centrifugation and then transferred 
into fresh tubes. Pre-cleared cell lysates (500 μl) were incubated with 10 μg 
anti-FLAG antibody and 50 μl of lgG agarose beads overnight at 4°C, with gentle 
rotation. Cell lysates were then subjected to centrifugation and agarose beads were 
washed by resuspension and centrifugation three times in lysis buffer. Proteins were 
released from the beads by heating at 99 °C for 5 minutes, subsequent to the addition 
of loading buffer. Proteins were separated by SDS-PAGE, transferred to PVDF 
membrane and immunoblotted for GRK2 content. As a negative control, each lysate 
was incubated with purified agarose beads as appropriate to determine non-specific 
binding. To verify protein expression, 5% of each cell lysate taken prior to the 
pull-down experiment was assessed by immunoblotting in parallel with 
immunoprecipitated samples.  
2.15 Statistical analyses 
For multiple group comparisons, an initial analysis by ANOVA was followed by 
Dunnett’s multiple comparison test. The significance of difference for between 
unpaired groups was determined by Student’s t test for unpaired data. A value for P < 
0.05 on a two-sided test was taken as the minimum level of significance (Prism 4.0; 
GraphPad Software Inc., San Diego, CA).   
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3 RESULTS 
3.1 GRK2 protein expression in cultured VSMCs 
To determine GRK2 protein expression levels in cultured VSMCs from WKY and 
SHR rats, I performed immunoblotting. GRK2 protein was detected at approximately 
80 kilodaltons (Figure 3.1A). The expression of GRK2 protein in VSMCs from SHRs 
was significantly elevated by 50±7% compared to normotensive WKY rats (p<0.05, 
Figure 3.1B). This result is consistent with our previous data in human hypertension 
(Gros et al, 1997, Gros et al, 1999) as well as animal models (Gros et al, 2000), which 
suggests an association between increased GRK2 expression and hypertension, 
confirming that the phenotype persisted in cultured VSMCs.  
3.2 Alteration of GRK2 protein expression by adenoviral infection 
To alter GRK2 protein expression levels, I utilized adenoviral constructs to infect 
VSMCs. To determine the infection efficiency of our adenoviral constructs, WKY and 
SHR VSMCs were infected with increasing concentrations of GRK2 or SiGRK2 
adenovirus. GFP and SiGFP adenovirus constructs were used as controls. GRK2 
expression was enhanced by increasing concentrations of GRK2 virus in both WKY 
and SHR VSMCs (Figure 3.2), whereas increasing concentrations of SiGRK2 virus 
led to attenuation of GRK2 expression (Figure 3.3). Western blots were used to 
determine the virus concentration needed to increase or decrease GRK2 expression 
levels by approximately 50%.   
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Figure 3.1. GRK2 protein expression in cultured VSMCs from WKY and SHR 
rats.  Cells were washed with PBS and lysed with ice-cold lysis buffer. 50 μg of 
protein were loaded on a 10% SDS-PAGE. After transfer, the PVDF membrane was in 
turn incubated with a 1:1000 GRK2 antibody and a 1:5000 anti-rabbit secondary 
antibody. GRK2 protein bands were then detected by ECL assay. A. GRK2 protein 
was detected at approximately 80 kilodaltons. B. Densitometric analysis of SHR 
GRK2 content was expressed as a percentage of GRK2 in WKY rats. *P<0.05 vs. 
WKY. Data represent means ± SEM from 3 independent experiments performed under 
identical conditions.   
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Figure 3.2. GRK2 protein expression in WKY and SHR VSMCs infected by 
increasing concentrations of GRK2 adenovirus.  Cells were infected by increasing 
concentrations of GRK2 adenovirus, GFP virus was used as control. Medium was 
changed once after 24 hours. VSMCs were lysed 48 hours post-infection and used for 
Western blotting. A. GRK2 protein was detected at approximately 80 kilodaltons. B. 
Densitometric analysis of GRK2 content was expressed as a percentage of GFP 
control, respectively. Data represent means ± SEM from 4 independent experiments 
performed under identical conditions.   
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Figure 3.3. GRK2 protein expression in WKY and SHR VSMCs infected by 
increasing concentrations of SiGRK2 adenovirus.  Cells were infected by 
increasing concentrations of SiGRK2 adenovirus, SiGFP virus was used as control. 
Medium was changed once after 24 hours. VSMCs were lysed 48 hours post-infection 
and used for Western blotting. A. GRK2 protein was detected at approximately 80 
kilodaltons. B. Densitometric analysis of GRK2 content was expressed as a 
percentage of GFP control, respectively. Data represent means ± SEM from 4 
independent experiments performed under identical conditions.   
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3.3 The effects of altering GRK2 protein expression levels on 
Gq-mediated signaling in VSMCs from WKY and SHR rats 
To examine the effects of altering GRK2 protein expression levels on Gq- 
mediated ERK activation, I examined the short-term (5 minutes) effects of angiotensin 
II and vasopressin. The effects of these hormones on ERK activation were compared 
with that of platelet-derived growth factor (PDGF, hormone acting through a tyrosine 
kinase receptor pathway, as opposed to a GPCR pathway). Both WKY and SHR 
VSMCs were infected with GRK2 or SiGRK2 adenovirus to achieve a 50% change in 
GRK2 protein expression level. Western blot results showed that all treatments 
significantly increased phospho-ERK1/2. Treatment with angiotensin II (Figure 3.4) 
and vasopressin (Figure 3.5) both led to significant enhancements in phospho-ERK 
levels in SHR cells compared to WKY cells. In addition, GRK2 over-expression 
greatly increased ERK activation in both cells. On the other hand, knocking down 
GRK2 resulted in a reduction of ERK phosphorylation. However, PDGF-induced 
ERK activation was not altered by changing GRK2 content (Figure 3.6). Taken 
together, these results suggested that altering GRK2 expression led to a corresponding 
change in certain vasoconstrictor mediated Gq signaling.   
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Figure 3.4. Short-term effect of angiotensin II on mitogen-activated protein 
kinase activity as assessed by phospho-ERK.  VSMCs were infected with GRK2 
or SiGRK2 adenovirus. After serum starvation for 24 hours, cells were incubated in 
the presence or absence of 1 μM angiotensin II for 5 minutes and then lysed with 
ice-cold lysis buffer. Densitometric analysis of phospho-ERK1/2 content was 
normalized to their own basal (untreated) condition. Total-ERK1/2 was used as 
loading control. *P<0.05. Data represent the means ± S.E.M. from 3 to 6 independent 
experiments performed under identical conditions.   
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Figure 3.5. Short-term effect of vasopressin on mitogen-activated protein kinase 
activity as assessed by phospho-ERK.  VSMCs were infected with GRK2 or 
SiGRK2 adenovirus. After serum starvation for 24 hours, cells were incubated in the 
presence or absence of 1 μM vasopressin for 5 minutes and then lysed with ice-cold 
lysis buffer. Densitometric analysis of phospho-ERK1/2 content was normalized to 
their own basal (untreated) condition. Total-ERK1/2 was used as loading control. 
*P<0.05. Data represent the means ± S.E.M. from 3 to 6 independent experiments 
performed under identical conditions.   
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Figure 3.6. Short-term effect of PDGF on mitogen-activated protein kinase 
activity as assessed by phospho-ERK.  VSMCs were infected with GRK2 or 
SiGRK2 adenovirus. After serum starvation for 24 hours, cells were incubated in the 
presence or absence of 20 ng/ml PDGF for 5 minutes and then lysed with ice-cold 
lysis buffer. Densitometric analysis of phospho-ERK1/2 content was normalized to 
their own basal (untreated) condition. Total-ERK1/2 was used as loading control. Data 
represent the means ± S.E.M. from 3 to 6 independent experiments performed under 
identical conditions.   
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3.4 The effects of altering GRK2 protein expression levels on 
Gs-mediated signaling in VSMCs from WKY and SHR rats 
To assess the effects of over-expression or knocking down of GRK2 on Gs 
mediated signaling, I performed the arborization assay. In VSMCs, isoproterenol (ISO) 
mediates a progressive arborization process, characterized by a generalized retraction 
and an increase in central cellular volume. This effect can be mimicked by forskolin 
(FSK), which increases intracellular cAMP by a more direct effect on adenylyl 
cyclase activation. We evaluated arborization responses as a read out of β- adrenergic 
dependant cAMP production. Analogous to the impaired vasodilator effects of ISO 
reported previously in intact vessels from hypertensive animals and humans (Feldman 
& Gros, 1998), the ISO-mediated arborization response was significantly attenuated in 
VSMCs from SHRs compared with WKY rats (p<0.05, Figure 3.7A). In contrast, 
FSK-stimulated arborization was not significantly different between WKY and SHR 
(Figure 3.7B).  
To further examine the effects of altering GRK2 expression levels on ISO- 
mediated arborization, VSMCs were infected with GFP, SiGFP, GRK2 or SiGRK2 
adenovirus. Over-expression of GRK2 in WKY VSMCs impaired ISO-mediated 
arborization by 47% compared with GFP control (p<0.05, Figure 3.8A), whereas 
knocking down GRK2 expression in SHR VSMCs resulted in an improved ISO- 
mediated arborization (by 56%, p<0.05, Figure 3.8B). These results demonstrated that 
increased GRK2 expression attenuated certain vasodilator mediated Gs signaling.   
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Figure 3.7. Isoproterenol- and forskolin-induced arborization in VSMCs from 
WKY rats and SHRs.  VSMCs were cultured on 35-mm dishes. After serum 
starvation for 24 hours, cells were incubated for 15 minutes in a temperature 
controlled chamber maintained at 37°C on an inverted microscope, then treated with 
either A. 10 μM ISO or B. 10 μM FSK. The progression of the arborization response 
was measured in the dark using time-lapse video microscopy. The extent of 
arborization was assessed by determining the change in image intensity using the 
threshold setting within the image analysis software. The change in image intensity at 
40 minute time point was expressed as a percentage of basal intensity (before the 
addition of drug). *P<0.05 vs. WKY. Data represent the means ± S.E.M. from 4 
independent experiments performed under identical conditions.   
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Figure 3.8. The effects of altering GRK2 expression levels on isoproterenol- 
mediated arborization.  A. WKY VSMCs were cultured onto 35-mm dishes, 
infected with GFP or GRK2 adenovirus for 24 hours before being serum-starved for 
another 24 hours. Cells were incubated for 15 minutes in a temperature controlled 
chamber maintained at 37°C on an inverted microscope, then treated with 10 μM ISO. 
The extent of arborization was assessed by determining the change in image intensity 
using the threshold setting within the image analysis software. The change in image 
intensity at the 40 minute time point was expressed as a percentage of basal intensity 
(before the addition of drug). *P<0.05 vs. GFP control. B. SHR VSMCs were cultured 
onto 35-mm dishes, infected with SiGFP or SiGRK2 adenovirus for 24 hours before 
being serum-starved for another 24 hours. The same protocol was followed as 
described above. *P<0.05 vs. SiGFP control. Data represent the means ± S.E.M. from 
4 independent experiments performed under identical conditions.   
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3.5 The effects of altering GRK2 protein expression levels on 
WKY VSMC contractility 
To determine the contractile reactivity of cultured VSMCs, I utilized a silicone 
wrinkle assay as previously described (Boswell et al, 1992, Gros et al, 2011a, Harris et 
al, 1980). To assess GPCR-mediated vasodilation, via activation of Gs, the dose 
response profile of the β-adrenergic receptor agonist, ISO (0.1 nM-10 µM) was 
assessed. This vasodilator response was compared to FSK-mediated vasodilation (0.1 
nM-10 µM), which reflected a direct activation of adenylyl cyclase. VSMCs isolated 
from WKY rats were infected with GFP, GRK2 or SiGRK2 adenovirus. ISO-mediated 
relaxation was impaired following GRK2 over-expression as compared to GFP- 
infected cells, whereas SiGRK2 gene-transfer did not further enhance ISO-mediated 
vasodilation (Figure 3.9). In addition, the extent of FSK-stimulated VSMC relaxation 
was not significantly changed by GRK2 over-expression as compared to GFP- or 
SiGRK2- infected VSMCs (Figure 3.10). These results suggested that increased 
GRK2 expression attenuated Gs-mediated vasodilation in cultured VSMCs.   
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Figure 3.9. Isoproterenol mediated dose-dependent relaxation in VSMCs isolated 
from WKY rats.  WKY VSMCs were infected with GFP, SiGRK2 or GRK2 
adenovirus. 24 hours after infection, they were subcultured onto 35 mm dishes 
containing siliconized cover slips. Dishes were mounted in a temperature- controlled 
chamber at 37 °C on an inverted microscope. After 10 minutes of baseline recording, 
increasing doses of ISO were given to VSMCs at 5 minutes intervals. Contractile 
responses were assessed using time-lapse video microscopy. Wrinkle area was 
quantified using bright image thresholding, where the relaxation was reflected as 
decreased intensity. Data are representative of means ± S.E.M. from 4-9 independent 
experiments performed under identical conditions. Over-expression of GRK2 impairs 
ISO-mediated relaxation.    
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Figure 3.10. Forskolin mediated dose-dependent relaxation in VSMCs isolated 
from WKY rats.  WKY VSMCs were infected with GFP, SiGRK2 or GRK2 
adenovirus. 24 hours after infection, they were subcultured onto 35 mm dishes 
containing siliconized cover slips. Dishes were mounted in a temperature- controlled 
chamber at 37 °C on an inverted microscope. After 10 min of baseline recording, 
increasing doses of FSK were given to VSMCs at 5 min intervals. Contractile 
responses were assessed using time-lapse video microscopy. Wrinkle area was 
quantified using bright image thresholding, where the relaxation was reflected as 
decreased intensity. Data are representative of means ± S.E.M. from 4-11 independent 
experiments performed under identical conditions. 
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Taken together, the above data suggested that GPCR-mediated Gq and Gs 
signaling can be regulated by altering GRK2 expression. This may contribute to the 
regulatory role of GRK2 in hypertension. The primary function of GRK2 is 
phosphorylating activated receptors and in turn leading to receptor desensitization and 
internalization. It has been suggested that estradiol and aldosterone have rapid 
vascular effects during hypertension, which are in part mediated by a recently 
identified GPCR, named GPR30. Here I investigate the effect of GPR30 in aortic 
function upon different agonist treatments, and potential regulation of GPR30 by 
GRK2.  
3.6 GPR30 protein expression in heart and aorta tissues as well as 
cultured VSMCs 
To determine the expression level of GPR30 in hearts and aortas from WKY and 
SHR rats, isolated tissues were homogenized in lysis buffer and the resultant 
supernatants were collected for immunoblotting. GPR30 protein content in hearts 
(Figure 3.11 A, B) and aortas (Figure 3.11 C, D) obtained from SHRs was 
significantly reduced as compared to WKY rats. Interestingly, this was opposite to the 
expression pattern of GRK2 in these animals. Thus we hypothesize that GPR30 
mediated cell signaling may be impaired in SHRs and this may related to the up- 
regulation of GRK2.  
In regard to cultured cells, our previous studies have showed that persistent 
70 
 
 
expression of GPR30 was detectable by RT-PCR in cultured vascular ECs (Gros et al, 
2011b), but declined in cultured VSMCs (Ding et al, 2009, Gros et al, 2011b). I also 
examined the GPR30 protein expression in cultured VSMCs. As demonstrated in 
Figure 3.12, GPR30 was expressed and detected in freshly isolated VSMCs (passage 
0, day 0). However, it was lost in culture (P0, day 4 and 6, as well as P1 and P2).   
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Figure 3.11. Assessment of GPR30 protein expression in isolated hearts and 
aortas from WKY and SHR rats.  Freshly isolated hearts and aortas were washed 
with ice-cold PBS, transferred into lysis buffer, chopped into small pieces with 
dissecting scissors, homogenized using a disposable pestle system and then 
centrifuged at 16000xg for 10 minutes, at 4˚C. The resultant supernatants were 
collected for western blotting. Proteins were separated by SDS-PAGE, transferred to 
PVDF membrane and immunoblotted for GPR30 content. A. Representative 
immunoblot of GPR30 expression in hearts. B. Densitometric analysis of GPR30 
content expressed in hearts as a percentage of WKY. C. Representative immunoblot 
of GPR30 expression in aortas. D. Densitometric analysis of GPR30 content 
expressed in aortas as a percentage of WKY. *P<0.05 vs. WKY. Data represent the 
mean ± S.E.M. from 4 independent experiments performed under identical conditions.   
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Figure 3.12. GPR30 protein expression in cultured VSMCs from WKY rats.  
VSMCs were isolated from aorta of WKY rats. Indicated passages of cells were 
washed with PBS and lysed with ice-cold lysis buffer. Proteins were separated by 
SDS-PAGE, transferred to PVDF membrane and immunoblotted for GPR30 content. 
GPR30 protein was detected at approximately 55 kilodaltons. GPR30 was expressed 
in freshly isolated VSMCs (passage 0, day 0). However, it was lost in culture (P0, day 
4 and 6, as well as P1 and P2).   
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3.7 Assessment of GPR30 mediated vascular reactivity in aortic 
rings 
Furthermore, I examined the potential effect of GPR30 activation on vascular 
reactivity. Aortic rings from WKY rats were cut and suspended in KPSS under 
optimal tension (0.75g) in individually double-walled organ baths maintained at 37°C 
and gassed with 5% CO2 and 95% O2. The constriction response to phenylephrine (PE) 
was quantified by determination of the area under the curve as described in methods. 
Aldosterone (Aldo) and G1 both appeared to act as agonists of GPR30. As shown in 
Figure 3.13 and 3.15, Aldo and G1 both caused attenuation of PE-mediated 
vasoconstriction in aortic ring segments. G15 has been suggested to be a GPR30 
antagonist. 1 μM G15 alone had no effect on this PE-mediated constriction, but it 
inhibited the vasodilatory effect of 10 pM Aldo (Figure 3.14). Interestingly, in contrast, 
G15 did not block the effect of G1 (Figure 3.16). I further examined the effect of G15 
and G1 in endothelium-denuded aortic rings. G15 alone had a very weak 
vasoconstrictor effect, and the vasodilatory effect of G1 was attenuated compared with 
endothelium-intact rings. Moreover, this G1 effect did not seem to be affected by G15. 
(Figure 3.17).   
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Figure 3.13. Aldosterone attenuates phenylephrine-mediated constriction in 
endothelium-intact aortic ring segments.  Aortic rings were submaximally 
constricted with 100 nM PE and allowed to reach a plateau that remained stable for 15 
minutes (baseline). After washout of PE, aortic rings were incubated in the indicated 
concentrations of Aldo. Aldo was added 2 minutes before PE. Two of four rings were 
assessed after sequential cycles of PE-mediated constriction without other treatment 
and thus served as temporal controls. PE-mediated constriction was quantified by 
determining the area under the curve generated by the data acquisition software. The 
effects of Aldo on PE-mediated contraction responses were expressed as a percentage 
of the baseline response normalized for temporal changes as assessed in the parallel 
control ring segments. Data represent means ± SEM for 5 independent experiments. 
*P<0.05 vs. control, ANOVA; Dunnett’s multiple comparison test.   
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Figure 3.14. G15 blocked aldosterone-induced attenuation of phenylephrine- 
mediated constriction in endothelium-intact aortic ring segments.  After baseline 
recording, aortic rings were incubated in the presence or absence of 1 μM G15, and 10 
pM of Aldo. G15 was added 15 minutes before the addition of PE. Aldo was added 2 
minutes before PE. One of four rings was assessed after sequential cycles of 
PE-mediated constriction without other treatment and thus served as temporal control. 
PE-mediated constriction was quantified by determining the area under the curve. The 
effects of G15 and Aldo on PE-mediated contraction responses were expressed as a 
percentage of the baseline response normalized for temporal changes as assessed in 
the parallel control ring segment. *P<0.05, Data represent means ± SEM for 6 
independent experiments.   
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Figure 3.15. G1 attenuates phenylephrine-mediated constriction in endothelium- 
intact aortic ring segments.  After baseline recording, aortic rings were incubated in 
the indicated concentrations of G1. G1 was added 2 minutes before PE. Two of four 
rings were assessed after sequential cycles of PE-mediated constriction without other 
treatment and thus served as temporal controls. PE-mediated constriction was 
quantified by determining the area under the curve generated by the data acquisition 
software. The effects of G1 on PE-mediated contraction responses were expressed as a 
percentage of baseline response normalized for temporal changes as assessed in the 
parallel control ring segments. Data represent means ± SEM for 5 independent 
experiments. *P<0.05 vs. control, ANOVA; Dunnett’s multiple comparison test.   
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Figure 3.16. G15 did not block G1-induced attenuation of phenylephrine- 
mediated constriction in endothelium-intact aortic ring segments.  After baseline 
recording, aortic rings were incubated in the presence or absence of 1 μM G15, and 
the indicated concentrations of G1. G15 was added 15 minutes before the addition of 
PE. G1 was added 2 minutes before PE. One of four rings was assessed after 
sequential cycles of PE-mediated constriction without other treatment and thus served 
as temporal control. PE-mediated constriction was quantified by determining the area 
under the curve generated by the data acquisition software. The effects of G15 and G1 
on PE-mediated contraction responses were expressed as a percentage of baseline 
response normalized for temporal changes as assessed in the parallel control ring 
segment. Data represent means ± SEM for 5 independent experiments.   
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Figure 3.17. The effect of G15 and G1 in endothelium-denuded aortic rings.  The 
endothelial layer was removed by gentle rubbing and flushing with distilled water. 
The absence of functional endothelium was inferred by the loss of 
methylcholine-mediated relaxation in PE-preconstricted rings. After baseline 
recording, aortic rings were incubated in the presence or absence of 1 μM G15, and 
the indicated concentrations of G1. G15 was added 15 minutes before the addition of 
PE. G1 was added 2 minutes before PE. One of four rings was assessed after 
sequential cycles of PE-mediated constriction without other treatment and thus served 
as temporal control. PE-mediated constriction was quantified by determining the area 
under the curve generated by the data acquisition software. The effects of G15 and G1 
on PE-mediated contraction responses were expressed as a percentage of baseline 
response normalized for temporal changes as assessed in the parallel control ring 
segment. Data represent means ± SEM for 5 independent experiments.   
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3.8 The effects of GPR30 agonist in cultured EC 
Our previous study (Liu et al, 2003) and current data suggested that Aldo and G1 
caused different responses in endothelium denuded rings compared with endothelium 
intact rings. I further examined the effect of different GPR30 agonists in cultured ECs. 
It has been suggested that GPR30 is related to EC growth and apoptosis (Gros et al, 
2011b). Thus, I utilized a wound healing assay to estimate the effect of GPR30 
activation on EC migration and proliferation. As shown in Figure 3.18, neither 10 nM 
estrodial nor 10 pM aldosterone produced any appreciable effect in this assay. 
However, wound healing of ECs was much slower when treated with 1 μM G1, and 
surprisingly this effect was not blocked by 1 μM G15. To investigate if this G1 effect 
was dose-dependent, I examined the effect of increasing doses of G1 (0.03 μM-3 μM) 
on wound healing in the presence or absence of 1 μM G15 pretreatment (Figure 3.19 
A, B). Wound healing of ECs is relatively sensitive to G1, within the 0.1-1 μM range, 
and G15 did not block the effects of G1 (Figure 3.19 C). These data indicated that the 
effect of G1 on ECs proliferation might be GPR30 independent. I also knocked down 
GPR30 protein expression in ECs using SiGPR30 adenovirus. As demonstrated in 
Figure 3.20, knocking down GPR30 expression in ECs did not attenuate the G1 effect. 
To further examine the specificity of this G1 effect in different cells and confirm the 
independency of this effect from GPR30, I performed parallel experiments using 
VSMCs. 1 μM G1 did not alter the wound healing, and GPR30 over-expression did 
not enhance the effect of G1 (Figure 3.21). All these results together reinforced the 
idea that this G1 effect on wound healing was GPR30 independent and EC specific.   
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Figure 3.18. Wound healing of ECs in response to estradiol, aldosterone or G1 
(with or without G15 pretreatment).  Cells were nearly confluent (~90%) in 35 
mm dishes. A sterile 10 μl pipet tip was used to scratch a wound through the cells 
perpendicular to a line drawn on the bottom of the dish. After changing the medium, 
cells were pretreated in the presence or absence of the GPR30 antagonist G15 (1 μM), 
and then treated with vehicle or GPR30 agonist estradiol (10 nM), aldosterone (10 pM) 
or G1 (1 μM). Wound area was then inspected microscopically and pictures were 
taken every 24 hours. The open gaps were calculated as percentage of basal area using 
image analysis software. Data represent means ± SEM for 5 independent experiments.   
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Figure 3.19. Wound healing of ECs in response to increasing doses of G1 (with or 
without G15 pretreatment).  Cells were nearly confluent (~90%) in 35 mm dishes. 
A sterile 10 μl pipet tip was used to scratch a wound through the cells perpendicular to 
a line drawn on the bottom of the dish. A. After changing the medium, cells were 
treated with vehicle or the indicated doses of G1 and wounds were assessed as 
described in methods. B. Cells were pretreated with 1 μM G15, and then treated with 
vehicle or the indicated doses of G1 and wounds were assessed as described in 
methods. C. Data obtained in these experiments were calculated as area under the 
curve. Pretreatment of G15 did not block the effect of G1. Data represent means ± 
SEM for 4 independent experiments.   
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Figure 3.20. Wound healing of ECs in response to aldosterone, estradiol or G1 
(with or without SiGPR30 virus infection).  ECs were infected with SiGFP or 
SiGPR30 adenovirus. Forty-eight hours post-infection, cells were nearly confluent 
(~90%) in 35 mm dishes. A sterile 10 μl pipet tip was used to scratch a wound through 
the cells perpendicular to a line drawn on the bottom of the dish. After changing the 
medium, cells were treated with vehicle or GPR30 agonist aldosterone (10 pM), 
estradiol (10 nM) or G1 (1 μM). Wound area was then inspected microscopically and 
pictures were taken every 24 hours. The open gaps were calculated as percentage of 
basal area using image analysis software. Data represent means ± SEM for 3 
independent experiments.   
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Figure 3.21. Wound healing of VSMCs in response to aldosterone, estradiol or G1 
(with or without GPR30 virus infection).  VSMCs were infected with GFP or 
GPR30 adenovirus. Forty-eight hours post-infection, cells were nearly confluent 
(~90%) in 35 mm dishes. A sterile 10 μl pipet tip was used to scratch a wound through 
the cells perpendicular to a line drawn on the bottom of the dish. After changing the 
medium, cells were treated with vehicle or GPR30 agonist aldosterone (10 pM), 
estradiol (10 nM) or G1 (1 μM). Wound area was then inspected microscopically and 
pictures were taken every 24 hours. The open gaps were calculated as percentage of 
basal area using image analysis software. Data represent means ± SEM for 3 
independent experiments.   
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In total, we have studied the effect of GPR30 in both aortic rings and cultured 
vascular cells. Earlier data have shown that the expression of GPR30 is reduced in 
tissues from SHRs. One possible interpretation of the down-regulation of GPR30 in 
SHRs is elevated receptor internalization and degradation. Here, we examine the 
possibility that GRK2 is able to phosphorylate GPR30 and regulate its desensitization, 
internalization and degradation.  
3.9 Localization of GRK2 and GPR30 in VSMCs 
To investigate whether GPR30 can co-localize with GRK2, I performed double 
immunofluorescence assay. Since GPR30 expression is greatly diminished in cultured 
VSMCs, I reintroduced GPR30 by infecting VSMCs with FLAG-tagged GPR30 
adenovirus. Cells were visualized through a Zeiss LSM 410 confocal microscope 
equipped with a Krypton / Argon laser using a 63× oil immersion lens. GRK2 was 
located uniformly in the cytosol, while GPR30 was more localized to the nucleus. After 
being treated with 1 pM aldosterone or 1 μM G1, more GPR30 transferred to the cell 
membrane. However, little or no co-localization between GPR30 and GRK2 was 
observed under basal or stimulated condition (Figure 3.22).  
3.10 Potential interaction between GRK2 and GPR30 in VSMCs 
To further explore the possibility of interaction between GRK2 and GPR30, a 
co-IP experiment was performed. VSMCs isolated from WKY rats were infected with 
adenovirus encoding GFP or FLAG-tagged GPR30. Following IP with anti-FLAG, no 
GRK2 protein was detected, which suggested that there was no interaction between 
GRK2 and GPR30 in cultured VSMCs (Figure 3.23).   
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Figure 3.22. Localization of GRK2 and GPR30 in VSMCs from WKY and SHR 
rats.  VSMCs isolated from WKY and SHR rats were cultured in 60 mm dishes. 
Some dishes were infected with FLAG-tagged GPR30 adenovirus for 4 hours. 
Twenty-four hours post-infection, cells were seeded onto 35 mm glass bottom 
microwell dishes at 30-50% confluency. After incubation in the presence or absence of 
10 pM Aldo or 1 μM G1 for 15 minutes, cells were fixed, permeabilized and then 
labeled with mouse-anti-FLAG and rabbit-anti-GRK2 antibodies. Following washes 
with PBS, cells were probed with AlexaFluor 488 goat-anti-rabbit and AlexaFluor 594 
goat-anti-mouse secondary antibodies. DAPI was used to detect nuclei. Cells were 
visualized through a Zeiss LSM 410 confocal microscope equipped with a Krypton / 
Argon laser using a 63× oil immersion lens.   
20 micron 
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Figure 3.23. Protein co-immunoprecipitation of VSMC lysates from WKY rats.  
VSMCs isolated form WKY rats were infected with adenovirus encoding GFP or 
FLAG-tagged GPR30. Forty-eight hours post-infection, cells were treated in the 
presence or absence of 1 pM Aldo or 1 μM G1 for 15 minutes and then lysed with 
ice-cold lysis buffer. Pre-cleared cell lysates (500 μl) were incubated with 10 μg 
anti-FLAG antibody and 50 μl lgG agarose beads overnight at 4°C, with gentle 
rotation. Cell lysates were then subjected to centrifugation and agarose beads were 
washed by resuspension and centrifugation three times in lysis buffer. Proteins were 
released from the beads by heating at 99 °C for 5 minutes, subsequent to the addition 
of loading buffer. Proteins were separated by SDS-PAGE, transferred to PVDF 
membrane and immunoblotted for GRK2 content. To verify protein expression, 5% of 
each cell lysate taken prior to the pull-down experiment was assessed by 
immunoblotting in parallel with immunoprecipitated samples.   
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4 DISCUSSION 
4.1 Hypertension and GRK2 
Previous studies in both human and animal models have confirmed that with 
regard to short-term effects on vascular reactivity, the hypertensive state is 
characterized by impairment in vasodilator mechanisms (acting through GPCRs 
linked to Gs/adenylyl cyclase activation) (Feldman & Gros, 1998). We have also 
demonstrated that the growth regulatory effects of β-adrenoceptor activation (the 
prototype GPCR linked to Gs/adenylyl cyclase) are comparably impaired with regard 
to β-adrenergic-mediated effects on ERK activation (Gros et al, 2006).  
β-adrenergic-mediated vasodilation and β-adrenergic-stimulated adenylyl cyclase 
activation are impaired in hypertension. These effects have been demonstrated in both 
human and experimental models of hypertension and both in vivo and in vitro 
(Feldman & Gros, 1998). My studies have confirmed that this functional impairment 
in β-adrenergic-mediated responses is still apparent in cultured single cell vascular 
systems in spontaneously hypertensive rats, a commonly used genetic model of 
hypertension. It is noteworthy that analogous “durability” of altered regulation of 
adenylyl cyclase in hypertension has been reported in “immortalized” lymphoblasts 
from hypertensive patients (Siffert et al, 1995). The persistence of this “phenotype” of 
impaired β-adrenergic responses in cultured cell systems would suggest that these 
defects are not due to short-term in vivo regulatory effects in hypertension, which 
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would be expected to be diminished and ultimately be undetectable when assessed in 
vitro in cultured cells with ongoing passaging.  
My current studies also demonstrate that the expression of GRK2 protein in 
VSMCs from SHRs was significantly elevated compared to normotensive WKY rats 
(Figure 3.1). This result is consistent with our previous data in human hypertension 
(Gros et al, 1997, Gros et al, 1999) as well as animal models (Gros et al, 2000), which 
suggested an association between increased GRK2 expression and hypertension, 
confirming that this phenotype remained in these cultured VSMCs.  
Having confirmed that the increased GRK2 expression levels are maintained in 
cultured VSMCs from SHRs, I examined if these GRK levels could be manipulated in 
cultured VSMCs using over-expression and knockdown (SiRNA) techniques in 
conjunction with adenoviral constructs. Using both WKY and SHR VSMCs I was 
able to precisely increase and decrease the GRK2 protein content on demand (Figures 
3.2 and 3.3). Using this adenoviral approach I was able to either increase or decrease 
the GRK2 expression levels (by approximately 50%) similarly to what we had 
observed in comparing the WKY versus SHR VSMCs. Previous studies have 
demonstrated impaired ISO-mediated ERK activation in VSMCs from SHRs as 
compared to WKY (Gros et al, 2006). Therefore, I next examined the effects of 
increasing or decreasing GRK2 expression levels on ERK activation by vasopressin, 
angiotensin II (acting via Gq-activation) as well as PDGF. It was clear that under 
endogenous GRK2 expression levels that both vasopressin- and angiotensin II- 
mediated ERK activation responses were enhanced in VSMCs obtained from SHRs 
92 
 
 
(Figures 3.4 and 3.5). This effect seems to be GPCR-selective, since PDGF-mediated 
responses (not acting via GPCRs) were not altered when comparing WKY versus 
SHR VSMCs. Similarly GRK2 over-expression greatly increased ERK activation in 
both type of cells (Figures 3.4 and 3.5). On the other hand, knocking down GRK2 
resulted in a reduction of ERK phosphorylation (Figures 3.4 and 3.5). Taken together, 
these results suggested that altering GRK2 expression led to a corresponding change 
in certain vasoconstrictor mediated Gq signaling. In addition, manipulation of GRK2 
expression levels can clearly alter the phenotype of the VSMCs. That is, increasing 
GRK2 expression levels in WKY cells makes them appear similar in vasopressin and 
angiotensin II responses as unaltered SHR VSMCs and similarly knocking down 
GRK2 in SHR VSMCs (back to levels similar to WKY) makes them have responses 
that are like unaltered WKY VSMCs (Figures 3.4 and 3.5). All these manipulations 
appear to be GPCR-specific since PDGF-mediated ERK activations were not 
significantly altered by increasing or decreasing GRK2 expression levels in either cell 
type (Figure 3.6).  
To further examine the potential of increasing or decreasing GRK2 expression 
levels in isolated cultured VSMCs, I utilized the arborization assay and silicone 
wrinkle assay and the responses of vasodilator mediated Gs signaling pathways. I 
observed that isoproterenol-mediated arborization was significantly attenuated in 
VSMCs from SHRs as compared to WKY VSMCs (Figure 3.7a). In contrast, 
forskolin-stimulated arborization was not significantly different between WKY and 
SHR (Figure 3.7b). Altering the GRK2 expression levels, could either impair 
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ISO-mediated arborization in GRK2 over-expressing WKY VSMCs, whereas 
knocking down GRK2 expression using SiRNA in SHR VSMCs resulted in an 
improved ISO-mediated arborization (Figure 3.8). Similarly, in the wrinkle assay, 
ISO-mediated relaxation was impaired following GRK2 over-expression (Figure 3.9) 
while FSK-stimulated VSMC relaxation (Figure 3.10) was not altered by the 
over-expression of GRK2.  
Taken together, GPCR-mediated Gq and Gs signaling can be regulated by acutely 
altering GRK2 expression. This may contribute to the regulatory role of GRK2 in 
hypertension which is a developmental disease (i.e. with developmental aging). 
Nevertheless, the ultimate goal of this series of studies was to utilize adenoviral 
constructs to manipulate the GRK2 expression in isolated aortic ring segments 
obtained from WKY and SHR rats using an organ culture approach. Unfortunately in 
many of our preliminary experiments we were unable to get either sufficient protein 
expression and/or tissue viability following the adenoviral infections and therefore 
abandoned this line of research. Although, manipulation of GRK2 expression in an 
acute setting may someday become viable for the vasculature in the setting of 
hypertension, GRK2 will probably remain a potential future target with novel 
therapeutics (small molecules, stem cells, etc). Indeed in the setting of heart failure 
great progress has been made with the use of altering GRK2 expression and disease 
outcome using small molecule approaches.  
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4.2 GPR30, hypertension and GRK2 
I also examined the potential role of a newly discovered GPCR, named GPR30, in 
vascular reactivity, wound healing and the possible interaction with GRK2. The 
interest in GPR30 has grown substantially in recent years. This was in part due to its 
initial discovery as a G protein-coupled receptor for steroid hormones especially 
estrogen (hence the suggested name change to GPER1, G protein estrogen receptor-1), 
but also more recently for aldosterone. In addition, we were interested in studying this 
receptor due to the link between aldosterone and estrogen with cardiovascular disease.  
Our previous studies demonstrated that aldosterone and estrogen both stimulate 
vascular smooth muscle cell contraction via PI3 kinase-mediated mechanisms and that 
aldosterone can mediate vasodilation via an endothelial-dependent pathway (Liu et al, 
2003). We have also delineated that these effects can be mediated by their classical 
receptors, MR and ER, and importantly, that the effects of both estradiol and 
aldosterone are enhanced by the expression of GPR30, a dynamically regulated 
receptor (Gros et al, 2011a). My initial studies focused on the expression levels of 
GPR30 in tissues obtained from 10 week old normotensive WKY and hypertensive 
SHRs. I demonstrated that GPR30 protein content in hearts and aortas obtained from 
SHRs was significantly reduced as compared to WKY rats (Figure 3.11). Interestingly, 
the reduction in GPR30 in SHR is in contrast to the increase in GRK2 expression. 
Whether this reduction in GPR30 expression is related to hypertension remains to be 
determined. Our initial experiments examining the expression levels in isolated tissue 
extracts or VSMCs protein lysates were performed with one of the only useable 
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commercially available antibody (MBL International) available against GPR30. 
Unfortunately, during the course of these experiments the company stopped producing 
the antibody. We were therefore unable to complete the assessment of GPR30 
expression in younger (5 week old) normotensive WKY and SHR rats. I have tried 
many different antibodies from different companies without any luck of detecting 
GPR30 in tissue and/or cell extracts. I even examined lysates from cells in which we 
over-expressed our flag-tagged GPR30 (with adenovirus) and could detect GPR30 
expression as assessed with the M2 (flag-tag) antibody but could not detect GPR30 
expression using the many different commercially available GPR30 antibodies.  
The loss of GPR30 expression in VSMCs in culture (Figure 3.12) has potentially 
significant implications. For both aldosterone and estradiol, the balance of their 
vasodilator vs. vasoconstrictor effects are reflective of the balance of their effects at 
endothelial vs. smooth muscle cells. Any enhancement of vascular smooth muscle 
mediated contractile effects, as might be seen with increased GPR30 expression, 
would be expected to tip the balance towards greater vasoconstrictor effects. Thus, 
dynamic regulation of GPR30 expression in VSMCs might be a potential mechanism 
regulating the overall contractile effects of both aldosterone and estrogens. 
Interestingly, this dynamic regulation of GPR30 expression in vascular smooth muscle 
cells is seen in vivo following vascular injury, while MR and ER receptor expression 
is maintained (R. Gros, Q. Ding, et al., unpublished observations). If this is a 
generalized phenomenon, then GPR30- mediated enhancement of aldosterone- and 
estradiol- stimulated contractile responses might be expected to be important in the 
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pathobiological responses to vascular injury and perhaps hypertension or other 
cardiovascular diseases.  
In the current study, the potential effect of GPR30 activation on vascular 
reactivity was assessed, using an approach that had been previously used to delineate 
the vasodilator and/or vasoconstrictor effects of aldosterone in isolated aortic ring 
segments (Liu et al, 2003). Our previous study suggested that the effect of Aldo to 
attenuate vasoconstrictor responses was endothelial/NO dependent. First, the ability of 
Aldo to attenuate vasoconstrictor responses was lost after endothelial denudation. In 
fact, in the absence of the endothelium, the effect of Aldo was converted to a 
vasoconstrictor response, reminiscent of the pattern of response to acetylcholine in 
endothelium-intact versus denuded preparations (Touyz et al, 1994). Second, in rings 
from SHR, which demonstrate endothelial dysfunction (Konishi & Su, 1983), the 
ability of Aldo to attenuate vasoconstrictor responses was lost. Lastly, the effect of 
Aldo to attenuate vasoconstriction was lost after inhibition of NOS activity by 
L-NMMA (Liu et al, 2003). Based on these previous data, I examined the effects of 
aldosterone and G1 in isolated aortic ring segments. Both aldosterone and G1 were 
able to attenuate PE-mediated vasoconstriction in isolated endothelium-intact aortic 
ring segments (Figures 3.13 and 3.15). These studies confirmed our previous findings 
(Liu et al, 2003) regarding the ability of aldosterone to mediate vasodilation in 
endothelium- intact ring segments as well as implicating GPR30 as a potential 
mediator of vasodilation since G1 was also able to attenuate PE-mediated constriction. 
Therefore, I examined the effects of G15 on either aldosterone or G1-mediated 
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vasodilation, which has been suggested to be a GPR30-specific antagonist. 
Interestingly, only G15 pre-treatment was able to inhibit the vasodilatory effect of 
aldosterone (Figure 3.14), and not G1 (Figure 3.16). The reason for the discrepancy is 
not currently known, but warrants further investigation in the future perhaps with 
newer and different GPR30 agonists. Interestingly, I did observe that removal of the 
endothelium was associated with a reduction in G1-mediated vasodilation (Figure 
3.17). This observation leads me to examine the effects of different GPR30 agonists 
(eg. aldosterone, G1) on cultured endothelial cells. Previous studies have suggested a 
potential role of GPR30 in regulating cellular growth and apoptosis (Gros et al, 
2011b). Therefore, I utilized the wound healing assay to examine the effect of GPR30 
activation on EC migration and proliferation. My initial studies examined the effects 
of estrogen, aldosterone and G1 on wound healing (Figure 3.18). Interestingly, only 
G1 had a significant effect on slowing wound healing as compared to estrogen or 
aldosterone, but this was not altered by pre-treatment with G15 (Figure 3.18). To 
further examine this effect, I performed dose-response experiments with G1 in the 
absence and presence of G15 (Figure 3.19). Surprisingly, wound healing of ECs was 
very sensitive to G1, within a 0.1-1 μM range, and again G15 did not block the effects 
of G1. Due to the inability of G15 to block the G1 response in endothelial cells, I 
utilized a SiRNA approach to knockdown GPR30 expression. Despite knocking down 
GPR30 expression in endothelial cells, G1 was still able to significantly inhibit wound 
healing (Figure 3.20). This inability of G15 to block G1 responses in either isolated 
ring segments or cultured endothelial cells or by knocking down GPR30 expression 
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suggests that G1 may act as an agonist on receptor(s) other than GPR30. Based on 
GPR30 knocking down and parallel experiments using VSMCs, this G1 effect on 
wound healing could be GPR30 independent and EC specific.  
In total, we have studied the effect of GPR30 in both aortic rings and cultured 
vascular cells. Earlier data have shown that the expression of GPR30 is reduced in 
tissues from SHRs. One possible interpretation of the down-regulation of GPR30 in 
SHRs is elevated receptor internalization and degradation. In the current study, I 
examined the possibility that GRK2 is able to interact and/or phosphorylate GPR30 
and regulate its desensitization, internalization and degradation. In double 
immunofluorescence assay, little or no co-localization between GPR30 and GRK2 
was observed under basal or stimulated condition (Figure 3.22). 
Co-immunoprecipitation data also suggested that there was no direct interaction 
between GRK2 and GPR30 in cultured VSMCs (Figure 3.23). Explanation for these 
data could be: 1) there was no endogenous GPR30 expression in cultured VSMCs, or 
GPR30 over-expression using adenovirus infection could affect the binding between 
GPR30 and GRK2; 2) other GRKs or protein kinases could bind to GPR30 and be 
responsible to the desensitization of GPR30; 3) there is controversy about the 
localization of GPR30. It has been suggested that GPR30 is predominately localized 
to the endoplasmic reticulum (ER), and that only minor amounts of receptor are 
detectable at the cell surface (Cheng et al, 2011). If this is right, then it is unlikely that 
GRK2 could interact with GPR30 because GRK2 normally tends to phosphorylate 
receptors located on the plasma membrane.  
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4.3 Summary and conclusions 
In summary, my studies have demonstrated that acute regulation of GRK2 expression 
levels may be important in regulating the function of vascular smooth muscle cells in 
culture. Overwhelming data has implicated GRKs in cardiovascular diseases including 
hypertension. This would suggest that a better understanding of the potential 
regulation of GRK2 (and other GRKs) and will therefore be an important target for 
future investigation. Whether this can be done in tissue and/or in vivo remains to be 
determined, but may require novel therapeutics (stem cells, small molecules etc.). In 
addition, I have demonstrated the potential role of the recently identified steroid 
receptor, GPR30 in mediating vascular reactivity as well as the potential reduced 
expression of this receptor in hypertensive animals. What role this reduced expression 
and/or altered signaling has in the hypertensive state remains to be determined. 
Cardiovascular diseases, such as hypertension are very prevalent and affect many 
Canadians. Therefore a better understanding of the regulation of vascular smooth 
muscle cells and endothelial cells under both physiological and pathological 
conditions remains an important focus.   
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